-
Mashup Score: 5The Targeted Pulse: Orca-T Triumphs in GVHD Prevention, Ide-Cel Elicits Durable Responses in MM, and More - 10 month(s) ago
A handful of positive news highlights new treatments: Orca-T’s superior outcomes in hematologic malignancies, 225Ac-FL-020 receiving fast track for prostate cancer, the addition of glofitamab leading to greater efficacy in DLBCL, and real-world data demonstrating lenvatinib’s effectiveness in RAI-refractory thyroid cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1Columvi combination extends OS in transplant-ineligible R/R DLBCL in phase III trial - The Cancer Letter - 10 month(s) ago
In the phase III STARGLO study of Columvi (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) versus Rituxan (rituximab) in combination with GemOx (R-GemOx) for people with relapsed or refractory diffuse large B-cell lymphoma who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, or who […]
Source: cancerletter.comCategories: General Medicine News, Oncologists1Tweet-
.@genentech's Columvi combination extends OS in transplant-ineligible R/R #DLBCL in phase III trial https://t.co/OjUflhGBLr https://t.co/JHx7yNToHr
-
-
Mashup Score: 0Different Options Discussed for DLBCL in Later-Lines of Treatment - 11 month(s) ago
During a Case-Based Roundtable® event, Matthew Ulrickson, MD, considered treatments for patients with relapsed/refractory diffuse large B-cell lymphoma with event participants in the second article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
During a Case-Based Roundtable® event, Matthew Ulrickson, MD, considered treatments for patients with relapsed/refractory #DLBCL. @BannerHealth https://t.co/dLNpzIuLnJ
-
-
Mashup Score: 15Krish Patel, MD, Talks Gilteritinib, Other Novel Frontline Therapies in DLBCL | Blood Cancers Today - 11 month(s) ago
“Having something that could cure patients after failing CAR-T is huge,” host Dr. Chadi Nabhan said during the episode.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🚨 Out now! The latest "HemOnc Pulse" episode with @chadinabhan featuring @KrishPatelMD, of @ProvSwedCancRes. 🎙️ They discuss novel frontline therapies in the lymphoma space, including the bispecific antibody gilteritinib. #DLBCL 🎧 Listen here! https://t.co/AyJlXtikzZ https://t.co/ECgfNlyaYc
-
-
Mashup Score: 0Krish Patel, MD, Talks Gilteritinib, Other Novel Frontline Therapies in DLBCL | Blood Cancers Today - 11 month(s) ago
“Having something that could cure patients after failing CAR-T is huge,” host Dr. Chadi Nabhan said during the episode.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🚨 Out now! The latest "HemOnc Pulse" episode with @chadinabhan featuring @KrishPatelMD, of @ProvSwedCancRes. 🎙️ They discuss novel frontline therapies in the lymphoma space, including the bispecific antibody gilteritinib. #DLBCL 🎧 Listen here! https://t.co/AyJlXtikzZ https://t.co/ECgfNlyaYc
-
-
Mashup Score: 0Alencar Discusses Treatment Choices After Early Relapse of DLBCL - 11 month(s) ago
During a Case-Based Roundtable® event, Alvaro Jose Alencar, MD, moderated a peer discussion on treatment options for a patient with diffuse large B-cell lymphoma whose disease relapsed eight months after completion of standard R-CHOP.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Alvaro Jose Alencar, MD, moderated a peer discussion on treatment options for a patient with #DLBCL whose disease relapsed eight months after completion of standard R-CHOP. @SylvesterCancer https://t.co/stSyFPD22i
-
-
Mashup Score: 1Experience and Sequencing Guide Third-Line DLBCL Therapy Selection - 12 month(s) ago
During a Case-Based Roundtable® event, Matthew Ulrickson, MD, discussed experiences with loncastuximab and other targeted treatments in patients with diffuse large B-cell lymphoma with event participants in the first article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Matthew Ulrickson, MD, discussed experiences with loncastuximab and other targeted treatments in patients with diffuse large B-cell lymphoma. #DLBCL | @BannerHealth https://t.co/T0e0HTUx85
-
-
Mashup Score: 0Krish Patel, MD, Talks Gilteritinib, Other Novel Frontline Therapies in DLBCL | Blood Cancers Today - 1 year(s) ago
“Having something that could cure patients after failing CAR-T is huge,” host Dr. Chadi Nabhan said during the episode.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🚨 Out now! The latest "HemOnc Pulse" episode with @chadinabhan featuring @KrishPatelMD, of @ProvSwedCancRes. 🎙️ They discuss novel frontline therapies in the lymphoma space, including the bispecific antibody gilteritinib. #DLBCL 🎧 Listen here! https://t.co/AyJlXtikzZ https://t.co/ECgfNlyaYc
-
-
Mashup Score: 1
Extrachromosomal DNA was highly expressed in 18 DLBCL cell lines, especially relapsed or refractory cases, and may function as a powerful prognostic indicator.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
A multiomics analysis shows how inhibiting a gene signaling pathway might work in treating #DLBCL. Researchers theorize that circular DNA independent of chromosomes is involved in cancer cell development, disease heterogeneity, and drug resistance. 🧬📰 https://t.co/eaQhx5hwfb https://t.co/xVQE5m2hWA
-
-
Mashup Score: 4
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet-
“We determined that two common and easily measured blood tests can identify in advance which [DLBCL] patients are at high risk for poor outcomes after treatment with CD19-targeted CAR-T cells,” said Marco Davila, MD, PhD. Keep reading: https://t.co/7pT5U3vaDl @MarcoLDavila #DLBCL https://t.co/sGYZjNwLYK
-
A handful of positive news highlights new treatments: Orca-T’s superior outcomes in hematologic malignancies, 225Ac-FL-020 receiving fast track for prostate cancer, the addition of glofitamab leading to greater efficacy in #DLBCL, & more! https://t.co/8E5eXPh1LL